<DOC>
	<DOCNO>NCT01500824</DOCNO>
	<brief_summary>This open-label multi-center Phase 2 efficacy safety study crizotinib East Asian patient advance Non-Squamous NSCLC harbor translocation inversion event involve ALK gene locus receive one prior chemotherapy regimen advance NSCLC regimen must platinum-based . Primary objective study assess anti-tumor activity safety profile crizotinib . Secondary objective evaluate clinical efficacy include median progression-free survival ( PFS ) 1-year PFS rate , overall survival ( OS ) , disease control rate ( DCR ) 6 12 week , time response ( TTR ) , duration response ( DR ) .</brief_summary>
	<brief_title>A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase ( ALK ) Positive Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Proven diagnosis locally advance metastatic nonsquamous cell carcinoma lung Positive translocation inversion event involve ALK gene locus Patients must progressive disease one prior chemotherapy regimen . This regimen must platinumbased may include maintenance therapy . Evidence personally sign date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment . Current treatment another therapeutic clinical trial . Prior therapy directly target ALK . Any follow within 3 month prior start study treatment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , congestive heart failure , cerebrovascular accident include transient ischemic attack . Ongoing cardiac dysrhythmias NCI CTCAE Grade &gt; =2 , uncontrolled atrial fibrillation grade , QTc interval &gt; 470 msec . Pregnancy breastfeed . Use drug food know potent CYP3A inducers/inhibitors/substrates narrow therapeutic index . Known HIV infection Known interstitial lung disease interstitial fibrosis Other severe acute chronic medical condition ( include severe gastrointestinal condition diarrhea ulcer ) psychiatric condition , laboratory abnormality would impart , judgment investigator and/or sponsor , excess risk associate study participation study drug administration , would , therefore , make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Crizotinib</keyword>
	<keyword>ALK</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Asian</keyword>
</DOC>